Michael Raggio, MD
Pulmonary Disease · Hattiesburg, MSNPI 1265493332
Payments from drug & device makers
Across 485 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- GSK$2K
- AstraZeneca$897
- Mylan Specialty L.p.$853
- Boehringer Ingelheim$438
- Grifols USA, LLC$425
- plus $3K from 33 others
What the payments were for
- Consulting fees$3503%
- Travel & lodging$7837%
- Food & beverage$7,75068%
- Education$2,50022%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $3,419 |
| GSK | 194 | $2,378 |
| AstraZeneca | 44 | $897 |
| Mylan Specialty L.p. | 45 | $853 |
| Boehringer Ingelheim | 27 | $438 |
| Grifols USA, LLC | 25 | $425 |
| Jazz Pharmaceuticals Inc. | 7 | $270 |
| Actelion Pharmaceuticals US, Inc. | 11 | $269 |
| Viatris Specialty LLC | 18 | $239 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $200 |
| Electromed, Inc. | 20 | $198 |
| Mallinckrodt Hospital Products Inc. | 10 | $197 |
| Sanofi | 9 | $197 |
| Regeneron Healthcare Solutions, Inc. | 9 | $195 |
| Amgen | 5 | $130 |
| Johnson & Johnson | 1 | $121 |
| Genentech USA, Inc. | 7 | $113 |
| Merck | 4 | $87 |
| Baxter Healthcare | 3 | $76 |
| Harmony Biosciences LLC | 5 | $74 |
| Philips North America LLC | 3 | $59 |
| United Therapeutics Corporation | 3 | $55 |
| Shionogi Inc | 3 | $51 |
| Novartis | 3 | $50 |
| Inspire Medical Systems, Inc. | 2 | $44 |
| Inari Medical, Inc. | 3 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Bayer | 2 | $36 |
| Pfizer | 2 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| La Jolla Pharmaceutical Company | 1 | $20 |
| Argenx US, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| AbbVie | 1 | $18 |
| Insmed, Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $16 |
| 3b Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,385
- LUMRYZ$200
- XYWAV$150
- XYREM$150
- Monarch Platform$121
How this compares
$11,383 in reported general payments places this provider in the 70th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 47 | $587,611 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 34 | $509,401 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 486 | $384,554 |
| Breo ElliptaFluticasone/Vilanterol | 280 | $131,258 |
| Bosentan | 11 | $91,826 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 128 | $78,217 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 119 | $74,260 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $38,707 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 592 | $22,482 |
| Arnuity ElliptaFluticasone Furoate | 36 | $9,665 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $8,164 |
| Ipratropium Bromide | 261 | $7,887 |
| Ventolin HfaAlbuterol Sulfate | 97 | $7,315 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $6,317 |
| XareltoRivaroxaban | 11 | $5,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat | $438 | $670,035181 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $2,378 | $608,324944 claims |
| Insmed, Inc.Arikayce | $16 | $509,40134 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $269 | $91,82611 claims |
| AstraZenecaBreztri Aerosphere | $897 | $38,70743 claims |
| Johnson & JohnsonXarelto | $121 | $5,95811 claims |
| MerckDulera | $87 | $4,34413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Hattiesburg
- L AldredHattiesburg$76K
- Walid YounisHattiesburg$15K
- Tamer HudaliHattiesburg$15K
- Lewis NeeseHattiesburg$9K
- Kevin KinlochHattiesburg$6K
- Randolph RossHattiesburg$5K
- Charles McCollumHattiesburg$4K
- Andrew RognessHattiesburg$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.